# US 2024/0197795 A1 · Assessment and treatment of depression, anxiety, or related disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197795 A1
- Document ID: US20240197795A1
- Status: Published application
- Kind: A1
- Application number: 18/006,940
- Filed: 2021-07-27
- Published: 2024-06-20
- Earliest claimed: 2020-07-27
- Assignees: Duke University; Emoory University; University of California Davis
- Applicants: Duke University; Emoory University; University of California, Davis
- Inventors: Rima F. Kaddurah-Daouk; Augustus John Rush, JR.; Boadie W. Dunlop; Oliver Fiehn; Christopher R. Brydges; W. Edward Craighead; Helen Mayberg
- Web page: https://patentgrep.com/patent/US20240197795A1

## CPC

- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61P 25/00: Drugs for disorders of the nervous system
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- C12P 17/10: Nitrogen as only ring hetero atom
- C12Y 401/99001: Tryptophanase (4.1.99.1)
- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- C12R 2001/145: Clostridium
- G01N 2800/30: Psychoses; Psychiatry
- G01N 2800/304: Mood disorders, e.g. bipolar, depression
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Described herein are methods of identifying, characterizing, and treating depression and anxiety in a subject by modulating indoles associated with tryptophan metabolism in the subject and subject's gut microbiome.

## Claims

### Claim 1

A method for treating a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or a combination thereof by modulating the gut microbiome composition or enzymatic activity of the subject, the method comprising:
(a) increasing the level of indole-3-propionic acid producing bacteria;
(b) decreasing the level of indoxyl sulfate producing bacteria;
(c) inhibiting bacterial enzymes that produce indoxyl sulfate;
(d) activating bacterial enzymes that produce indole-3-propionic acid; or
a combination of any of (a)-(d).

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is undergoing cognitive behavioral therapy, treatment with an anti-depressant, or a combination thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the anti-depressant comprises one or more of selective serotonin reuptake inhibitors (SSRI), tricyclic anti-depressants (TCA), selective serotonin and norepinephrine reuptake inhibitors (SNRI), monoamine oxidase inhibitors (MAOI), anxiolytics, antipsychotics, or combinations thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the anti-depressant comprises one or more of citalopram (Celexa®), escitalopram (Lexapro®), duloxetine (Cymbalta®), fluoxetine (Prozac®), paroxetine (Paxil®), sertraline (Zoloft®), trazodone (Desyrel®), lorazepam (Ativan®), oxazepam (Serax®), aripiprazole (Abilify®), clozapine (Clozaril®), haloperidol (Haldow®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), ziprasidone (Geodon®), amitriptyline, amoxapine, desipramine (Norpramin®), doxepin, imipramine (Tofranil®), nortriptyline (Pamelor®), protriptyline, trimipramine, or combinations thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the anti-depressant comprises escitalopram (Lexapro®), duloxetine (Cymbalta®), or a combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein the indole-3-propionic acid producing bacteria comprise Clostridium sporogenes.

### Claim 7 (depends on 6)

The method of claim 6, wherein increasing the level of indole-3-propionic acid producing bacteria comprises obtaining and administering to the subject probiotic Clostridium sporogenes.

### Claim 8 (depends on 1)

The method of claim 1, wherein the indoxyl sulfate producing bacteria comprise tryptophanase expressing bacteria.

### Claim 9 (depends on 1)

The method of claim 1, further comprising administering to the subject one or more therapeutic agents to trap and sequester indoxyl sulfate.

### Claim 10 (depends on 9)

The method of claim 9, wherein the therapeutic agent comprises AB-2004 or activated charcoal.

### Claim 11 (depends on 1)

The method of claim 1, further comprising administering to the subject one or more therapeutic agents to inhibit enzymatic activity of sulfotransferase liver enzymes that produce indoxyl sulfate.

### Claim 12 (depends on 11)

The method of claim 11, wherein the method prevents indoxyl sulfate from crossing the blood-brain barrier.

### Claim 13 (depends on 1)

The method of claim 1, further comprising administering to the subject one or more therapeutic agents to inhibit aryl hydrocarbon receptor activity of intestinal immune cells.

### Claim 14 (depends on 1)

The method of claim 1, further comprising:
measuring a concentration of one or more of the subject's tryptophan gut metabolites comprising one or more of indoxyl sulfate, indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof; and
determining ratios of indoxyl sulfate concentration to the concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, or indole-3-lactate.

### Claim 15 (depends on 14)

The method of claim 14, wherein the measuring the concentration of one or more tryptophan gut metabolites is repeated at least twice; wherein a first measurement is taken as a baseline reading and a second or subsequent measurement is taken following modulation of the gut microbiome composition, enzymatic activity, or combination thereof of the subject.

### Claim 16 (depends on 14)

The method of claim 14, wherein the measured concentrations and determined ratios are compared to a healthy control.

### Claim 17 (depends on 14)

The method of claim 14, wherein ratios are correlated with Hamilton Anxiety scores, Hamilton Depression scores, or Quick Inventory of Depressive Symptoms.

### Claim 18 (depends on 1)

The method of claim 1, wherein the method modulates a concentration of one or more tryptophan gut metabolites in the subject selected from indoxyl sulfate, indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the method reduces the concentration of indoxyl sulfate in the subject.

### Claim 20 (depends on 18)

The method of claim 18, wherein the method increases the concentration of indole-3-propionic acid in the subject.

### Claim 21 (depends on 1)

The method of claim 1, further comprising assessing disease severity of the subject prior to, during, or following modulation of the gut microbiome composition, enzymatic activity, or combination thereof of the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein assessing disease severity comprises the use of one or more disease assessment tests selected from a Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), a Hamilton Anxiety Rating Scale (HAM-A), or a Hamilton Depression Rating Scale (HAM-D).

### Claim 23

A method for treating a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combination thereof by characterizing the gut microbiome metabolic profile of the subject, the method comprising:
(a) obtaining one or more biological samples from the subject;
(b) measuring a baseline concentration of one or more tryptophan gut metabolites selected from indoxyl sulfate, indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof;
(c) determining baseline ratios of indoxyl sulfate concentration to the concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, and indole-3-lactate, wherein increased baseline ratios of indoxyl sulfate indicate that the subject is suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety or combination thereof; and
(d) administering a therapy to the subject when increased ratios of indoxyl sulfate are determined.

### Claim 24 (depends on 23)

The method of claim 23, wherein the subject is undergoing cognitive behavioral therapy, treatment with an anti-depressant, or a combination thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the anti-depressant comprises one or more of selective serotonin reuptake inhibitors (SSRI), tricyclic anti-depressants (TCA), selective serotonin and norepinephrine reuptake inhibitors (SNRI), monoamine oxidase inhibitors (MAOI), anxiolytics, antipsychotics, or combinations thereof.

### Claim 26 (depends on 25)

The method of claim 25, wherein the anti-depressant comprises one or more of citalopram (Celexa®), escitalopram (Lexapro®), duloxetine (Cymbalta®), fluoxetine (Prozac®), paroxetine (Paxil®), sertraline (Zoloft®), trazodone (Desyrel®), lorazepam (Ativan®), oxazepam (Serax®), aripiprazole (Abilify®), clozapine (Clozaril®), haloperidol (Haldol®), olanzapine (Zyprexa®), quetiapine (Seroquel®), risperidone (Risperdal®), ziprasidone (Geodon®), amitriptyline, amoxapine, desipramine (Norpramin®), doxepin, imipramine (Tofranil®), nortriptyline (Pamelor®), protriptyline, trimipramine, or combinations thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the anti-depressant comprises escitalopram (Lexapro®), duloxetine (Cymbalta®), or a combination thereof.

### Claim 28 (depends on 23)

The method of claim 23, wherein the measuring the concentration of one or more tryptophan gut metabolites is repeated at least twice, wherein a first measurement is taken as a baseline reading and a second or subsequent measurement is taken following administration of the therapy to the subject.

### Claim 29 (depends on 23)

The method of claim 23, wherein the measured baseline concentrations and determined baseline ratios are compared to a healthy control.

### Claim 30 (depends on 23)

The method of claim 23, wherein the therapy comprises one or more therapeutic agents to trap and sequester indoxyl sulfate.

### Claim 31 (depends on 30)

The method of claim 30, wherein the therapeutic agent comprises AB-2004 or activated charcoal.

### Claim 32 (depends on 23)

The method of claim 23, wherein the therapy comprises a probiotic gut bacterial strain that produces indole-3-propionic acid and does not produce indoxyl sulfate.

### Claim 33 (depends on 30)

The method of claim 30, wherein the probiotic gut bacterial strain comprises Clostridium sporogenes.

### Claim 34 (depends on 23)

The method of claim 23, wherein the therapy reduces tryptophanase expressing bacteria.

### Claim 35 (depends on 23)

The method of claim 23, wherein the therapy comprises one or more therapeutic agents to inhibit enzymatic activity of sulfotransferase liver enzymes that produce indoxyl sulfate.

### Claim 36 (depends on 23)

The method of claim 23, wherein the therapy comprises one or more therapeutic agents to inhibit aryl hydrocarbon receptor activity of intestinal immune cells.

### Claim 37 (depends on 23)

The method of claim 23, further comprising performing functional magnetic resonance imaging of the subject prior to, during, or following administration of the therapy to the subject to monitor changes in brain resting state functional connectivity.

### Claim 38 (depends on 23)

The method of claim 23, further comprising assessing disease severity of the subject prior to, during, and following administration of the therapy to the subject.

### Claim 39 (depends on 38)

The method of claim 38, wherein assessing disease severity comprises the use of one or more disease assessment tests selected from a Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), a Hamilton Anxiety Rating Scale (HAM-A), or a Hamilton Depression Rating Scale (HAM-D).

### Claim 40

A method for stratifying one or more subjects suffering from a neuropsychiatric disease, disorder, or condition, including depression, major depressive disorder, anxiety, or combinations thereof into subgroups based on individual gut microbiome composition, enzymatic activity, concentrations and ratios of metabolites produced by gut bacteria, or combinations thereof, the method comprising:
(a) obtaining one or more biological samples from the subjects;
(b) measuring a baseline concentration of one or more tryptophan gut metabolites selected from indoxyl sulfate, indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof;
(c) determining a baseline ratio of indoxyl sulfate concentration to concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof;
(d) stratifying the subjects into subgroups based on the determined baseline ratios of indoxyl sulfate concentration to concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof; and
(e) assessing disease severity of subjects in each stratified subgroup.

### Claim 41 (depends on 40)

The method of claim 40, wherein increased ratios of indoxyl sulfate concentration to concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, and indole-3-lactate indicate that the subject is suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof.

### Claim 42 (depends on 40)

The method of claim 40, wherein the measured baseline concentrations and determined baseline ratios are compared to a healthy control.

### Claim 43 (depends on 40)

The method of claim 40, wherein assessing disease severity of subjects in each stratified subgroup comprises using one or more disease assessment tests selected from a Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR), a Hamilton Anxiety Rating Scale (HAM-A), or a Hamilton Depression Rating Scale (HAM-D).

### Claim 44 (depends on 40)

The method of claim 40, further comprising administering a therapy to subjects in each stratified subgroup based on the assessed disease severity and the determined baseline ratios of indoxyl sulfate concentration to concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof.

### Claim 45 (depends on 44)

The method of claim 44, wherein the therapy comprises modulating the gut microbiome composition or enzymatic activity of the subject by:
(a) increasing the level of indole-3-propionic acid producing bacteria;
(b) decreasing the level of indoxyl sulfate producing bacteria;
(c) inhibiting bacterial enzymes that produce indoxyl sulfate;
(d) activating bacterial enzymes that produce indole-3-propionic acid; or
a combination of any of (a)-(d).

### Claim 46

Use of a therapeutic agent to trap and sequester indoxyl sulfate for the treatment of a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof.

### Claim 47

Use of an indole-3-propionic acid producing probiotic gut bacterial strain for the treatment of a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof.

### Claim 48 (depends on 47)

The use of claim 47, wherein the probiotic gut bacterial strain comprises Clostridium sporogenes.

### Claim 49

Use of a therapeutic agent to inhibit enzymatic activity of sulfotransferase liver enzymes that produce indoxyl sulfate for the treatment of a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof.

### Claim 50

Use of a therapeutic agent to inhibit aryl hydrocarbon receptor activity of intestinal immune cells for the treatment of a subject suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof.

### Claim 51

A method for treating a subject suffering from, or at risk of suffering from, immune metabolic depression, anxiety, or combinations thereof by characterizing the gut microbiome metabolic profile of the subject, the method comprising:
(a) obtaining one or more biological samples from the subject;
(b) measuring a concentration of one or more tryptophan gut metabolites selected from indoxyl sulfate, indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof;
(c) determining ratios of indoxyl sulfate concentration to the concentrations of indole-3-propionic acid, 5-methoxytryptamine, indole-3-acetate, indole-3-lactate, or combinations thereof, wherein increased ratios of indoxyl sulfate indicate that the subject is suffering from, or at risk of suffering from, depression, major depressive disorder, anxiety, or combinations thereof;
(d) measuring aryl hydrocarbon receptor activity of intestinal immune cells; and
(e) administering a therapy to the subject when increased ratios of indoxyl sulfate are determined.

### Claim 52 (depends on 51)

The method of claim 51, wherein the measured concentrations and determined ratios are compared to a healthy control.

### Claim 53 (depends on 51)

The method of claim 51, wherein the therapy comprises modulating the gut microbiome composition or enzymatic activity of the subject by:
(a) increasing the level of indole-3-propionic acid producing bacteria;
(b) decreasing the level of indoxyl sulfate producing bacteria;
(c) inhibiting bacterial enzymes that produce indoxyl sulfate;
(d) activating bacterial enzymes that produce indole-3-propionic acid; or
a combination of any of (a)-(d).

### Claim 54 (depends on 51)

The method of claim 51, wherein the therapy comprises one or more therapeutic agents to inhibit aryl hydrocarbon receptor activity of intestinal immune cells.
